Loading...
Dernières publications
-
Luce Barbat Du Closel, Nathalie Bonello-Palot, Yann Pereon, Andoni Echaniz-Laguna, Jean Philippe Camdessanche, et al.. Clinical and electrophysiological characteristics of women with X-linked Charcot-Marie-Tooth disease. European Journal of Neurology, 2023, 30 (10), pp.3265-3276. ⟨10.1111/ene.15937⟩. ⟨hal-04254200⟩
-
-
Joe-Elie Salem, Marie Bretagne, Baptiste Abbar, Sarah Leonard-Louis, Stéphane Ederhy, et al.. Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis. Cancer Discovery, 2023, 13 (5), pp.1100-1115. ⟨10.1158/2159-8290.CD-22-1180⟩. ⟨hal-04578810⟩
-
-
Corinna Preuße, Barbara Paesler, Christopher Nelke, Derya Cengiz, Thomas Müntefering, et al.. Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis. Acta Neuropathologica, 2022, 144 (2), pp.353-372. ⟨10.1007/s00401-022-02438-z⟩. ⟨hal-03830925⟩
-
Lee Nguyen, Marie Bretagne, Jennifer Arrondeau, Noel Zahr, Stephane Ederhy, et al.. Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. Journal for Immunotherapy of Cancer, 2022, 10 (4), pp.e004699. ⟨10.1136/jitc-2022-004699⟩. ⟨hal-03832478⟩
-
Lee Nguyen, Marie Bretagne, Jennifer Arrondeau, Noel Zahr, Stephane Ederhy, et al.. Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. Journal for Immunotherapy of Cancer, 2022, 10 (4), pp.e004699. ⟨10.1136/jitc-2022-004699⟩. ⟨hal-04002766⟩
-
-
Stéphane Ederhy, Perrine Devos, Bruno Pinna, Elisa Funck-Brentano, Baptiste Abbar, et al.. 8 F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography imaging for the diagnosis of immune checkpoint inhibitors associated myocarditis. Archives of cardiovascular diseases, 2022, ⟨10.1016/j.acvd.2021.12.001⟩. ⟨hal-03561783⟩
-
Pierre Bay, Marc Pineton de Chambrun, Vincent Rothstein, Matthieu Mahevas, Nicolas de Prost, et al.. Plasma exchange are not associated with better outcome in MDA5 rapidly-progressive interstitial lung disease. French Intensive Care Society International Congress 2022, 2022, paris, France. pp.54, ⟨10.1186/s13613-022-01016-6⟩. ⟨hal-03831253⟩
Chiffres clés
123
Publications avec texte intégral
Open Access
53 %
Mots clés
Anti-IgE IgG
Idiopathic inflammatory myopathies
Dermatomyositis
Fabry disease
AAV antibody
Pharmacology
Antisynthétase
Aged
Gene therapy
Myocarditis
B-lymphocyte
Abnormal movement
Aldosterone
Deep immune profiling
Muscle
Anti-synthetase syndrome
AAV vectors
Antiphospholipid syndrome
Antibody responses
COVID-19
Myopathy
Machine learning
Adult
AAV humoral immunity
Autoimmunity
IBM
Anti‐mitochondrial antibodies
Humans
Skeletal muscle
Biopsy
Anémie hémolytique
Acute Kidney Injury/epidemiology/etiology
Immune checkpoint inhibitors
Anticorps spécifique des myosites
Polymyositis
Multidisciplinarity
Anti-agalsidase antibodies
Autoantibodies
Anti-drug antibodies
Inborn errors of metabolism
Analyses multidimensionnelles
Data integration
Systems biology
Cytokines
Adjudication
Antibodies
Autoantibody
Female
Biomarkers
AAV vector
Inclusion body myositis
Biomarker
Bioelectrical impedance analysis
Adolescence
Outcome measures
Auto-antibodies
Anti-MDA5 autoantibodies
Adeno-associated vector
Anticorps anti-agalsidase
Inflammation
Myositis
AAV
Anti-interleukin-6
Middle Aged
Amyotrophic lateral sclerosis
Sphingosine-1-phosphate
Assisted communication devices
Immunotherapy
Anti-Mi2
Amyotrophy
Adverse drug reactions
Interstitial lung disease
DM
Interferon
Biomarqueurs
Antisynthetase
Active
IMNM
Auto-immunité
Case reports
Auto‐antibodies
Mass cytometry
Animals
B cell homeostasis
Adeno-associated virus
Myositis and muscle disease
Acid-alpha-glucosidase
Adeno-associated virus vector
Lysosomal storage diseases
Male
Cardio-oncology
Aldostérone
Inflammatory myopathy
Dependovirus/genetics/immunology
Cancer
Autoimmune diseases
Arthritis
Antisynthetase syndrome
Agalsidase
Prognosis